Humacyte (NASDAQ:HUMA – Get Free Report) is projected to post its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $1.1190 million for the quarter. Following the completion of the sale, the chief financial officer owned 267,213 shares of the company’s stock, valued at approximately $240,491.70. Also, Director Kathleen Sebelius purchased 56,818 shares of Humacyte stock in a transaction dated Tuesday, May 19th. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $6.25.